NCT01302015 is a NA clinical trial of RNL-Vascostem® in Buerger's Disease, sponsored by R-Bio.

Who is sponsoring NCT01302015?

NCT01302015 is sponsored by R-Bio.

What drugs are being tested in NCT01302015?

Interventions in NCT01302015: RNL-Vascostem®.

What condition does NCT01302015 study?

NCT01302015 studies Buerger's Disease.

Is NCT01302015 still recruiting?

NCT01302015 is currently completed. Last updated 3 June 2019.

Last reviewed 2019-06-03 · How we verify

NCT01302015

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease

Completed NA Last updated 3 June 2019

What this trial tests

NA trial testing RNL-Vascostem® in Buerger's Disease in 15 participants. Completed in 1 December 2013.

Timeline

1 December 2007

Primary endpoint
1 December 2013

1 December 2013

Quick facts

Lead sponsor	R-Bio
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 December 2007
Primary completion	1 December 2013
Estimated completion	1 December 2013
Sites	2 locations across South Korea

Drugs / interventions tested

RNL-Vascostem® — full drug profile →

Conditions studied

Buerger's Disease — all drugs for Buerger's Disease →

Sponsor

R-Bio — full company profile →

Who can join

Adults 20 to 80, any sex, with Buerger's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Treadmill Walking Distance
Time frame: 24 weeks
Improvement in TWD(Treadmill Walking Distance)

Sponsor's own description

The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Buerger's disease.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Adipose-Derived Stem Cells for Tissue Engineering and Regenerative Medicine Applications.
Dai R, Wang Z, Samanipour R, Koo KI, et al · · 2016 · cited 191× · PMID 27057174 · DOI 10.1155/2016/6737345
Tissue Engineering and Regenerative Medicine: Achievements, Future, and Sustainability in Asia.
Han F, Wang J, Ding L, Hu Y, et al · · 2020 · cited 153× · PMID 32266221 · DOI 10.3389/fbioe.2020.00083
Therapeutic angiogenesis of adipose-derived stem cells for ischemic diseases.
Zhao L, Johnson T, Liu D. · · 2017 · cited 137× · PMID 28583178 · DOI 10.1186/s13287-017-0578-2
Mesenchymal stem cell-based therapy for non-healing wounds due to chronic limb-threatening ischemia: A review of preclinical and clinical studies.
Huerta CT, Voza FA, Ortiz YY, Liu ZJ, et al · · 2023 · cited 36× · PMID 36818343 · DOI 10.3389/fcvm.2023.1113982
Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.
Shirbaghaee Z, Hassani M, Heidari Keshel S, Soleimani M. · · 2022 · cited 36× · PMID 36068595 · DOI 10.1186/s13287-022-03148-9
Growth factors for angiogenesis in peripheral arterial disease.
Gorenoi V, Brehm MU, Koch A, Hagen A. · · 2017 · cited 25× · PMID 28594443 · DOI 10.1002/14651858.cd011741.pub2
A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial Assessing the Safety and Efficacy of Intramuscular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Severe Buerger's Disease.
Ra JC, Jeong EC, Kang SK, Lee SJ, et al · · 2017 · cited 16× · PMID 28713639 · DOI 10.3727/215517916x693069

Verify or expand the search:

Other R-Bio trials

Trials by the same sponsor.

NCT04825730 — Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy · NA · not yet recruiting
NCT04821102 — Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration · NA · unknown
NCT04427930 — Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial · Phase 3 · active not recruiting
NCT03990805 — A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis · Phase 3 · completed
NCT03979898 — Safety and Effectiveness of Autologous Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With CP · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01302015 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by R-Bio
Last refreshed: 3 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01302015.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing